---
layout: default
title: Apis Cerana Whole Beef Liver Bombyx Mori Whole Bor
parent: 僅模型預測 (L5)
nav_order: 339
evidence_level: L5
indication_count: 0
---

# Apis Cerana Whole Beef Liver Bombyx Mori Whole Bor
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Allergen Complex (Apis Cerana / Corticotropin / Histamine / et al.): Insufficient Data for Repurposing Analysis

## One-Sentence Summary

This candidate consists of a 15-component biological mixture including insect whole-body extracts, animal-derived materials, a microbial antigen (*Borrelia burgdorferi*), and pharmacological agents (Corticotropin, Histamine dihydrochloride), resembling a multi-allergen immunotherapy or desensitization preparation.
No approved indication was found in the Taiwan (TFDA) database, and **TxGNN returned no predicted new indications** for this candidate.
As a result, a standard repurposing evidence evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indications on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — and none exists) |
| US Market Status | Not marketed (no TFDA licenses found) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction is available for this candidate, so a mechanistic justification for repurposing cannot be constructed at this time.

The drug INN string describes a heterogeneous mixture of 15 substances spanning insect whole-body antigens (Asian honeybee, silkworm, dog flea, common mosquito, house fly, Australian cockroach, paper wasp, fire ant, deer fly, black widow spider), animal organ extracts (beef liver, pig adrenal gland), a spirochete antigen (*Borrelia burgdorferi*), a peptide hormone (Corticotropin/ACTH), and a biogenic amine (Histamine dihydrochloride). This composition is consistent with a **multi-allergen desensitization or provocation-testing preparation** rather than a conventional small-molecule drug.

Because each component carries its own pharmacological profile and the mixture lacks a unified DrugBank entry, the TxGNN knowledge-graph cannot map it to a single drug node. This structural incompatibility — not a gap in clinical evidence — is the primary reason no predictions were generated. Resolving this requires decomposing the mixture into individual active substances and running predictions on each component separately.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

No TFDA authorizations on record for this drug string.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** All safety fields (key warnings, contraindications, drug–drug interactions) returned no data for this query. Given that the mixture contains potent biological materials — including a venomous arthropod extract (Latrodectus mactans / black widow spider), a live-organism antigen (Borrelia burgdorferi), and a vasoactive amine (Histamine dihydrochloride) — clinical use without verified safety documentation is inadvisable.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
TxGNN produced zero predicted indications, and the drug has no regulatory history in Taiwan, leaving no evidence base — clinical, regulatory, or model-derived — on which to build a repurposing case.

**To proceed, the following is needed:**

- **Decompose the mixture**: Split the 15-component INN into individual substances and resubmit each to the TxGNN pipeline separately (priority candidates: Corticotropin, Histamine dihydrochloride, Solenopsis invicta extract).
- **Identify the intended product class**: Confirm whether this is an allergen immunotherapy product, a homeopathic preparation, or a diagnostic reagent kit, as each class follows a different regulatory and evidence pathway.
- **Retrieve DrugBank IDs** for mappable components (Corticotropin: DB00716; Histamine: DB04660) to enable KG-based prediction on individual agents.
- **Retrieve original indication / package insert**: Search FDA NDC/NDA databases and TFDA for products containing this combination to establish the intended therapeutic context.
- **Safety documentation**: Obtain the full package insert or SDS for each biological component before any further analysis, given the presence of venom-derived and infectious-agent-derived materials.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

